{"id":295352,"date":"2026-03-05T00:00:00","date_gmt":"2026-03-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0020-2020-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-current-treatment-current\/"},"modified":"2026-03-31T10:23:19","modified_gmt":"2026-03-31T10:23:19","slug":"cutron0020-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-current-treatment-current-treatment-physician","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0020-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-current-treatment-current-treatment-physician\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Squamous Cell Carcinoma of the Head and Neck (US)"},"content":{"rendered":"<p>The treatment of non-nasopharyngeal <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally advanced setting, surgery with curative intent has been the standard of care; however, the recent approval of Keytruda (Merck &#038; Co.), supported by positive outcomes in KEYNOTE-689, introduces a novel potential approach for appropriately selected patients. In the recurrent or metastatic setting, <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr> inhibition with Erbitux (Eli Lilly) was historically a systemic option. In patients with <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr>\u2013expressing tumors, immune checkpoint inhibitors, including Keytruda and Opdivo (<abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>), along with their subcutaneous formulations (Keytruda Qlex and Opdivo Qvantig), are more frequently prescribed. This report evaluates the critical determinants influencing medical oncologists\u2019 prescribing choices in the treatment of non-nasopharyngeal <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What are the current treatment practices in locoregionally advanced and recurrent or metastatic non-nasopharyngeal <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, and which clinical factors influence treatment selection?<\/li>\n<li>What is the uptake of immune checkpoint inhibitors versus <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr>-targeted therapies in non-nasopharyngeal <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, and how does this differ from <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr> <abbr data-abbreviation-entity=\"8249\" title=\"combined positive score\">CPS<\/abbr>?<\/li>\n<li>What are the treatment rates for non-nasopharyngeal?<\/li>\n<li>What are the key drivers and constraints influencing the use of immune checkpoint inhibitors and <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr>-targeted therapies in unresectable or metastatic <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. medical oncologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Erbitux; Keytruda; Keytruda Qlex; Opdivo; Opdivo Qvantig<\/p>\n","protected":false},"template":"","class_list":["post-295352","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295352\/revisions"}],"predecessor-version":[{"id":575184,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295352\/revisions\/575184"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}